ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy
- 30 November 2007
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 122 (3) , 195-201
- https://doi.org/10.1016/j.ijcard.2006.11.076
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Clinical and Pharmacologic Study of the Epirubicin and Paclitaxel Combination in Women With Metastatic Breast CancerJournal of Clinical Oncology, 2001
- Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.Journal of Clinical Oncology, 1998
- Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.Journal of Clinical Oncology, 1997
- EpirubicinDrugs, 1997
- Cardiac disturbances during the administration of taxol.Journal of Clinical Oncology, 1991
- Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in ChildhoodNew England Journal of Medicine, 1991
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Adriamycin cardiomyopathy—risk factorsCancer, 1977
- A clinicopathologic analysis of adriamycin cardiotoxicityCancer, 1973